Poolbeg Pharma has dosed the first patient in its POLB 001 TOPICAL trial, testing a treatment to prevent cytokine release syndrome in multiple myeloma patients receiving teclistamab. The trial has expanded to University College London Hospital with more sites opening soon, showing strong interest from the hematology community. Interim data expected in late summer 2026 could be a key value milestone, while regulatory progress and commercial partner talks continue. This development aims to improve safety for patients undergoing advanced cancer immunotherapies.
Last week, US stock markets gained ground with the S&P 500 up 1.2% and Nasdaq Composite rising 1.7%, despite President Trump's announcement that the cease-fire with Iran had ended. Investors appeared to focus on ongoing US-Iran talks rather than the ...
The Goldman Sachs Future Health Care Equity ETF (GDOC) gained momentum after positive news from its largest holding, Eli Lilly (LLY), whose price target was raised by JPMorgan. GDOC has returned 11.8% over the past three months, recovering from earli...
